Full Text
The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer

Abstract

Authors

S. Djalalov D.M. Graham J. Beca J.S. Hoch M.S. Tsao N. Leighl

Back to Volume 17, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×